Source comparison
The Clinical Evidence: What Studies Show About Sermorelin vs Synthetic HGH
A 2003 randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism compared sermorelin acetate (administered at bedtime to coincide with natural GH peak) to recombinant human growth hormone in adults with documented GH deficienc
This comparison does not assign a generated winner or score.
- A 2003 randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism compared sermorelin acetate (administered at bedtime to coincide with natural GH peak) to recombinant human growth hormone in adults with documented GH deficiency. Both groups achieved similar increases in IGF-1 levels. Sermorelin subjects averaged a 35% increase from baseline, HGH subjects averaged 42%. But the sermorelin group maintained endogenous GH pulsatility throughout the 24-week study, while the HGH group showed complete suppression of natural GH secretion by week 8. Lean body mass gains were statistically equivalent between groups (sermorelin +2.1 kg, HGH +2.4 kg), but the sermorelin group reported fewer adverse events. Particularly joint stiffness and peripheral edema, which occurred in 18% of HGH subjects versus 6% of sermorelin subjects.
- A separate observational study from the University of Washington tracked metabolic outcomes in 87 adults using sermorelin off-label for body composition management over 12 months. Mean IGF-1 levels increased from 142 ng/mL at baseline to 198 ng/mL at 12 months. A clinically meaningful rise that remained within the physiological range for age. Visceral adipose tissue, measured by DEXA scan, decreased by an average of 12.3%, and fasting insulin improved by 14%. Importantly, endogenous GH secretion. Measured by overnight GH sampling. Remained intact at the 12-month mark, suggesting that sermorelin doesn't cause the pituitary downregulation seen with synthetic HGH.